CEO Jeff Galvin joins NBC 4 to discuss the success of AGT’s Phase 1 HIV gene and cell therapy clinical trial, as well as plans to advance to Phase 2 through Addimmune™ — a new spinoff company harnessing gene and cell therapy technologies for a potential HIV cure. Addimmune will focus solely on HIV research while building upon more than a decade of work by American Gene Technologies®. Join us as we Imagine A World Without HIV℠!
